Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Lignende værker

• Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
  af: Miles, David, et al.
  Udgivet: (2013)
• Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
  af: Baselga, José, et al.
  Udgivet: (2011)
• Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study
  af: Swain, Sandra M., et al.
  Udgivet: (2013)
• Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
  af: Swain, Sandra M., et al.
  Udgivet: (2015)
• Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
  af: Bianchini, Giampaolo, et al.
  Udgivet: (2017)